Daiichi Sankyo is a global pharmaceutical company that focuses on innovation in the areas of cardiovascular, renal, and metabolic diseases, as well as oncology. With a history dating back over a century, Daiichi Sankyo is committed to improving the lives of patients worldwide by developing new and effective treatments.
Cutting-edge research and development
Commitment to patient outcomes
Broad range of therapeutic areas
Global presence and partnerships
Edoxaban is an oral anticoagulant used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis and pulmonary embolism.
Quizartinib is an oral tyrosine kinase inhibitor used for the treatment of relapsed or refractory FLT3-ITD positive acute myeloid leukemia (AML). It works by inhibiting the activity of the FLT3 receptor, which is often mutated in AML.
Mirogabalin is an investigational drug that is being developed for the treatment of neuropathic pain. It acts as a selective ligand for the u03b12u03b4 subunit of voltage-dependent calcium channels, which play a key role in the transmission of pain signals.
Daiichi Sankyo focuses on cardiovascular, renal, and metabolic diseases, as well as oncology.
Edoxaban is used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis and pulmonary embolism.
Quizartinib is used for the treatment of relapsed or refractory FLT3-ITD positive acute myeloid leukemia (AML).
Mirogabalin is being developed for the treatment of neuropathic pain.
Daiichi Sankyo's competitors include Pfizer, Novartis, AstraZeneca, and Bayer.
